The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 10, 2023
Filed:
Mar. 03, 2016
Combination of a pd-1 antagonist and a vegf-r/fgfr/ret tyrosine kinase inhibitor for treating cancer
Applicants:
Merck Sharp & Dohme Llc, Rahway, NJ (US);
Eisai R&d Management Co., Ltd., Tokyo, JP;
Inventors:
Andrew Evan Denker, North Wales, PA (US);
Yu Kato, Tokyo, JP;
Kimiyo Tabata, Tokyo, JP;
Yusaku Hori, Tokyo, JP;
Assignees:
MERCK SHARP & DOHME LLC, Rahway, NJ (US);
Eisai R&D Management Co., Ltd., Tokyo, JP;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 31/47 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
A61K 31/47 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); A61K 2039/505 (2013.01); A61K 2300/00 (2013.01); C07K 2317/76 (2013.01);
Abstract
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a multi-RTK inhibitor, and the use of the combination therapies for the treatment of cancer. The multi-RTK inhibitor may be represented by Formula (I):